南京市鼓楼区集庆门大街 270 号苏宁环球国际中心 43 层 电话：025-85803866 传真：025-85803680 邮编：210003 北京国枫（南京）律师事务所 国枫律股字[2025]H0036 号 致：基蛋生物科技股份有限公司（贵公司） 北京国枫（南京）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2025 年第一次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《基 蛋生物科技股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的 召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜， 出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-041 基蛋生物科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (五) 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席9人； 2、 公司在任监事3人，出席3人； 3、 董事会秘书出席会议；其他高管列席会议。 二、 议案审议情况 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 9 月 15 日 (二) 股东大会召开的地点：南京市六合区沿江工业开发区博富路 9 号基蛋生 物科技股份有限公司四楼会议室 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，由董事长苏恩本主持。本次股东大会采用 现场投票和网络投票相结合的方式进行表决。会议的召集、召开、表决形式和程 序符合《公司法》《上海证券交易所股票上市规则》及《公司章程》等法律法规 及规范性文件的规定。 (一) 非累积投票议案 1、 ...

2025年9月10日，公司董事长苏恩本先生、公司财务总监倪文先生、公司董 事会秘书刘葱女士、公司独立董事万遂人先生、公司独立董事鞠熀先先生、公司 独立董事凌华女士出席了本次业绩说明会。公司就2025年半年度经营状况、财务 状况、产品等问题与投资者进行互动交流和沟通，在信息披露允许的范围内就投 资者普遍关注的问题进行了回答。 二、本次会议投资者提出的主要问题及公司的回复情况 公司在说明会上就投资者关心的问题给予了回答，主要问题及答复整理如下： 证券代码：603387 证券简称：基蛋生物 公告编号：2025-040 基蛋生物科技股份有限公司 关于 2025 年半年度业绩网上说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）于2025年9月10日 14:00-15:00在上证所信息网络有限公司上证路演中心平台（以下简称"上证路 演中心"）采用网络互动方式召开"基蛋生物2025年半年度业绩说明会"。关于 本次业绩说明会的召开事项，公司已于2025年8月30日在《上海证券报 ...

Group 1 - The company announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.09 yuan per share (tax included) for A-shares [2] - The record date for the dividend is set for September 12, 2025, and the ex-dividend date is September 15, 2025 [2]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-039 基蛋生物科技股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.09元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/12 | － | 2025/9/15 | 2025/9/15 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本507,153,517股为基数，每股派发现 金红利0.09元（含税），共计派发现金红利45,643,816.53元。 | 股份类别 | 股权登记日 | 最后交易 ...

Core Points - Getein Biotech, Inc. is holding its first extraordinary general meeting of shareholders in 2025 to discuss several key proposals aimed at improving corporate governance and operational efficiency [1][3][4] Group 1: Meeting Proposals - Proposal 1 involves the cancellation of the supervisory board and the amendment of the company's articles of association to enhance governance structure [3][4] - Proposal 2 includes multiple amendments to governance-related systems, such as the rules for board meetings, shareholder meetings, and the independent director work system [1][3][4] - The meeting will also address the abolition of the supervisory board's procedural rules and the revision of the external guarantee management system [1][3][4] Group 2: Meeting Procedures - The meeting is scheduled for September 15, 2025, at 14:00, and will be held both in-person and via an online voting system [2][3] - Shareholders must register and provide identification to participate, and they will have the right to speak and vote on the proposals presented [2][3] - Voting will be conducted through a named voting method, and all proposals will require a clear choice of "agree," "disagree," or "abstain" [2][3][4] Group 3: Governance Changes - The proposed changes aim to align the company's governance with the requirements of the Company Law and Securities Law of the People's Republic of China [3][4] - The amendments are designed to protect the rights of shareholders and ensure the company's operations are conducted in a transparent and efficient manner [3][4] - The company emphasizes the importance of maintaining order during the meeting and protecting the rights of all shareholders present [2][3]

基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议资料 基蛋生物科技股份有限公司 Getein Biotech,Inc. 2025 年第一次临时股东大会 会议资料 中国 南京 二〇二五年 九月 1 基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议资料 基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议资料目录 | 序号 | | 会议资料名称 | | --- | --- | --- | | 1 | | 基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议须知 | | 2 | | 基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议议程 | | 3 | | 基蛋生物科技股份有限公司 2025 年第一次临时股东大会会议议案 | | 议案 | 1 | 关于取消监事会并修订《公司章程》的议案 | | 议案 | 2.00 | 关于修订及制定公司治理相关制度的议案 | | 议案 | 2.01 | 关于修订《董事会议事规则》的议案 | | 议案 | 2.02 | 关于修订《股东会议事规则》的议案 | | 议案 | 2.03 | 关于废止《监事会议事规则》的议案 | | 议案 | ...

Core Viewpoint - The financial performance of 基蛋生物 (603387) for the first half of 2025 shows a significant decline in revenue and net profit compared to the previous year, indicating challenges in the domestic market and potential issues with accounts receivable management [1][6]. Financial Performance Summary - Total revenue for the first half of 2025 was 513 million yuan, a decrease of 17.0% year-on-year [1]. - Net profit attributable to shareholders was 109 million yuan, down 25.88% from the previous year [1]. - The gross margin was 69.36%, slightly up by 0.14% year-on-year, while the net margin fell to 20.05%, a decrease of 17.95% [1]. - The total of selling, administrative, and financial expenses was 146 million yuan, accounting for 28.39% of revenue, a slight decrease of 0.92% year-on-year [1]. - Earnings per share decreased to 0.21 yuan, down 27.59% year-on-year [1]. Accounts Receivable and Cash Flow - Accounts receivable amounted to 786 million yuan, representing 177.8% of the latest annual net profit, indicating a high level of receivables relative to profit [1][14]. - Operating cash flow per share was 0.29 yuan, down 9.74% year-on-year, reflecting reduced cash inflows from sales [1][10]. Changes in Financial Items - Significant changes in financial items included a 15.79% increase in trading financial assets due to an increase in investment bank financial products [2]. - A 42.15% decrease in accounts receivable financing was noted, attributed to a reduction in bank acceptance bills [2]. - Short-term borrowings increased by 18.87%, indicating a rise in short-term debt [3]. Cost Management - Operating costs decreased by 17.26%, in line with the drop in revenue [7]. - Sales expenses fell by 22.91% due to cost control measures, including reductions in travel and promotional expenses [7]. - Research and development expenses decreased by 9.66%, reflecting improved management and optimization of R&D projects [9]. Business Model and Market Position - The company's performance is primarily driven by R&D and marketing efforts, necessitating a thorough examination of the underlying factors influencing these drivers [13]. - The return on invested capital (ROIC) for the previous year was 5.96%, indicating average capital returns, with a historical median ROIC of 21.97% since its listing [12].

Group 1 - The company reported a revenue of 513 million yuan for the first half of 2025, representing a year-on-year decline of 17.00% [1] - The net profit attributable to the parent company was 109 million yuan, down 25.88% year-on-year [1] - The net profit excluding non-recurring items was 93.23 million yuan, reflecting a year-on-year decrease of 28.52% [1]

Group 1 - The company,基蛋生物, announced the resignation of its securities representative,谢玉鑫, due to job changes, and appointed王娇 as the new representative [1] - The company will hold its fourth board meeting on August 29, 2025, to review the appointment of the new securities representative [1] - For the year 2024, the company's revenue composition is 100% from in vitro diagnostics [1] Group 2 - As of the report, the market capitalization of基蛋生物 is 4.3 billion yuan [1]